Sanofi India Limited Stock Analysis

Operating cash flow was strong at Rs. 4,383 million and free cash flow was Rs. 4,126 million, implying a healthy 126.29% FCF conversion ratio. / Profitability remained robust despite lower revenue, with EBITDA margin improving to 27.51%, operating margin at 25.69%, and net profit margin at 17.59%. / The balance sheet is very strong with zero debt-to-equity, zero debt-to-assets, and cash equivalents of Rs. 2,629 million. / Working capital improved materially as inventory fell from Rs. 4,998 million to Rs. 3,116 million and trade receivables declined from Rs. 2,300 million to Rs. 1,767 million. / Return metrics are high, with ROE at 43.61% and ROA at 26.03%, indicating efficient use of capital and assets.

Revenue from operations declined 8.73% year on year to Rs. 18,374 million, showing that the business is currently facing top-line pressure. / Export sales dropped by Rs. 1,481 million due to the anticipated cessation of the Zentiva contract, highlighting customer or contract concentration risk. / The company recorded exceptional items of negative Rs. 273 million in FY2025, which weighs on earnings quality even though core profitability held up. / Liquidity is adequate but not especially conservative, with a quick ratio of 1.0 and current ratio of 1.63, so working capital discipline remains important. / The company recognized an additional Rs. 58 million employee benefit impact from the notified Labour Codes, and further impact remains uncertain pending final rules.

Zero debt structure with debt-to-equity of 0 and debt-to-assets of 0, providing maximum financial flexibility and eliminating refinancing or leverage risks / Exceptional profitability metrics with ROE of 43.61% and ROA of 26.03%, demonstrating superior capital efficiency despite the recent revenue decline / Strong free cash flow conversion at 126.29% FCF-to-profit ratio, generating Rs. 4,126 million with operating cash flow margin of 23.6%, enabling capital returns and strategic investments / Improved operational efficiency with EBITDA margin expanding to 27.51% despite 8.73% revenue decline, indicating pricing power and cost discipline / Solid liquidity position with current ratio of 1.63 and quick ratio of 1.0, plus working capital improvement from Rs. 4,998 million to Rs. 3,116 million inventory reduction

Significant revenue concentration risk materialized with Rs. 1,481 million (8.73% of annual revenue) loss from Zentiva contract cessation, creating a one-time headwind without identified replacement export contracts / Dividend payout ratio of 86.73% on depressed earnings leaves limited capital for investment in new product development, capacity expansion, or M&A to offset lost export revenue / Regulatory uncertainty from four consolidated Labour Codes notified November 2025, with Rs. 58 million recognized in FY 2025 and potential for additional liabilities upon final Central and State rules notification / Export dependency demonstrated by the magnitude of Zentiva contract impact; geographic revenue distribution not disclosed, indicating potential hidden concentration risks in remaining export markets / Exceptional items of negative Rs. 273 million in FY 2025 suggest one-time charges that may recur if demerger-related restructuring continues to impact results

Exceptional cash generation with operating cash flow of Rs. 4,383 million and free cash flow of Rs. 4,126 million, yielding an FCF margin of 22.22% and conversion ratio of 126.29% / Strong profitability metrics with EBITDA margin of 27.51%, net profit margin of 17.59%, ROE of 43.61%, and ROA of 26.03% despite revenue decline / Completely debt-free capital structure with zero debt-to-equity and debt-to-assets ratios, providing significant financial flexibility and interest coverage of 261.59x / Improved working capital management with inventory reduced from Rs. 4,998 million to Rs. 3,116 million and receivables declining from Rs. 2,300 million to Rs. 1,767 million / Substantial dividend payout of Rs. 123 per share for FY 2025 representing 86.73% payout ratio, demonstrating confidence in cash flows and shareholder returns

Revenue declined 8.73% YoY to Rs. 18,374 million with export sales dropping by Rs. 1,481 million due to Zentiva contract cessation, indicating customer concentration risk / Exceptional items of negative Rs. 273 million in FY 2025 impacted reported earnings quality and raise questions about one-time charges / Post-demerger operations following Consumer Healthcare business separation effective June 1, 2024 create uncertainty around the continuing business growth trajectory / Regulatory risk from implementation of four consolidated Labour Codes resulted in Rs. 58 million incremental employee benefit expense with potential for additional impact upon final rule notification / Current ratio of 1.63 and quick ratio of 1.0 indicate modest liquidity buffer, particularly given the high dividend payout ratio of 86.73%

EBITDA margin improved to 27.51% and operating margin was healthy at 25.69%, indicating resilient core profitability despite lower revenue. / Operating cash flow was strong at Rs. 4,383 million, with free cash flow of Rs. 4,126 million and FCF margin of 22.22%. / Balance sheet is conservatively positioned with debt-to-equity of 0, debt-to-assets of 0, and very high interest coverage of 261.59. / Working capital execution improved, with inventory reduced to Rs. 3,116 million from Rs. 4,998 million and receivables reduced to Rs. 1,767 million from Rs. 2,300 million. / Return profile remains strong with ROE at 43.61% and ROA at 26.03%, supported by asset turnover of 1.46.

Revenue from operations declined 8.73% YoY to Rs. 18,374 million, showing clear top-line contraction. / Export concentration risk is evident from the Rs. 1,481 million sales decline tied to anticipated Zentiva contract cessation. / Reported earnings included exceptional items of negative Rs. 273 million, affecting earnings consistency. / Dividend cash outflow of Rs. 4,422 million exceeded free cash flow of Rs. 4,126 million, contributing to a Rs. 209 million decline in cash during the year. / Regulatory cost risk is active: Labour Code assessment already led to Rs. 58 million incremental employee benefit expense, with further impact pending final rules.